The new method is used in combination with full-term caesarean section deliveries, and with millions of caesarean sections performed worldwide each year, it opens the potential for an unexploited reserve of stem cells and valuable bioactive molecules in the fluid surrounding the baby to be utilized.
“We showed that using our device, we can collect up to a litre of amniotic fluid at full-term caesarean deliveries. The collection added on average 90 seconds to the operation, and was safe for both mother and child,” says Associate Professor Andreas Herbst, lead clinician and a corresponding author of the study.
The collection device, which has been constructed with bio-inert plastics and 3D-printing techniques, forms a seal with the fetal cavity, enabling gentle and sterile collection of large volumes of amniotic fluid, while being completely safe for mother and baby. The collected fluid contains specialized cells with high therapeutic potential. The cell type that the current protocol purifies is called a Mesenchymal Stem Cell (MSC).
MSCs can obtained from other tissues in the body, and have already demonstrated therapeutic potential for immune and inflammatory-mediated diseases, for example, cardiovascular disease, diabetes, arthritis, and neurodegenerative disorders. However, the difficulty in acquiring sufficient numbers of these cells limits their broad use in cell therapy and tissue repair applications. “Full term amniotic fluid, being an easily obtainable and abundant tissue source, may be the solution for MSC based cell therapy and regenerative medicine applications”, says Associate Professor Niels-Bjarne Woods, a corresponding author in the study.
Since the collections involve planned Caesarean sections, no additional invasive medical procedures are needed for the MSC isolation, in contrast to MSC isolation from bone marrow.
The research group has also shown another potential use for MSCs purified from full-term amniotic fluid. By converting these cells to an embryonic-like stem cell state, they can potentially give rise to all different cell types of the body, including neural cells, blood cells and heart cells, among others.
“The combination of this novel device and the coupled cellular selection and cultivation methods could be transformative for the stem cell field, as large quantities of newborn-MSC’s can be provided by utilizing this waste material. The safety standards we adhere to are also a central component for gaining clinical acceptance. The obvious next step would be to evaluate these cells further in the laboratory and, if successful, in disease models”, says Dr Marcus Larsson, clinician and a corresponding author on the publication.
The long-term goal is that amniotic fluid collection will be adopted in clinics worldwide, and by doing so, the numbers of suitably matched MSCs obtained would rapidly increase to finally be sufficient to treat any genetically matched person in need of individualized MSC based therapy.
“Now that we have demonstrated the feasibility to access this neonatal MSC source, our hope is that many more research groups will start working with these cells. This will accelerate our understanding of their full therapeutic potential“, says Dr. Niels-Bjarne Woods.
MSCs are rare therapeutically useful cells
MSCs are a subset of precursor cells that can be found in very low frequencies in most human adult tissues, such as bone marrow and adipose tissue, and in neonatal tissue sources such as umbilical cord and placenta. The retrieval, however, is either complicated by the requirement for an invasive surgical procedure, or significant laboratory processing of the tissue. These aspects have already placed significant constraints on the numbers of patients able to undergo MSC based therapies. Thus, an alternative source of MSCs would be advantageous. These difficult to obtain cells are highly promising in cell therapy and regenerative medicine applications due to their ability to differentiate into specialized cell types and to suppress immune responses, which together promote regeneration of damaged tissue.
From the laboratory to the clinic
Based on the finding of the researchers involved in this study, a company was formed by the inventors and Lund University Innovation Systems. This company, Longboat Explorers AB, has the goal in the future to deliver amniotic fluid MSCs and other components from the fluid for the treatment of disease.
Publication: Term amniotic fluid: an unexploited reserve of mesenchymal stromal cells for reprogramming and potential cell therapy applications
Niels-Bjarne Woods, Ph.D., Associate Professor, Molecular Medicine and Gene Therapy, Lund University, Sweden
+46 46 222 3762
niels-bjarne [dot] woods [at] med [dot] lu [dot] se